Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 23;2(9):100402.
doi: 10.1016/j.xcrm.2021.100402. eCollection 2021 Sep 21.

WEE1i-ATRi combination therapy: a promising low-dose treatment for CCNE1-amplified gynecologic cancers

Liana Goehring  1 , Tony T Huang  1
Affiliations
Comment

WEE1i-ATRi combination therapy: a promising low-dose treatment for CCNE1-amplified gynecologic cancers

Liana Goehring et al. Cell Rep Med. .

Abstract

CCNE1 amplification is an oncogenic driver for many gynecologic cancers and is associated with poor patient outcomes. In this issue, Xu et al.1 identify a combination therapy that is responsive to high CCNE1-copy number ovarian and endometrial cancers using PDX models.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
CCNE1-driven gynecologic cancer models and mechanisms of combination treatment (A) Patient-derived xenograft (PDX) models of endometrial cancers (EMCAs) and high grade serous ovarian cancers (HGSOCs). Resected tumors are implanted into immunocompromised mice for translational assays. (B) Combination WEE1 and ATR inhibition treatment is synergistically toxic in HGSOC and EMCA PDX models through distinct molecular mechanisms.
See this image and copyright information in PMC

Comment on

References

    1. Xu H., George E., Kinose Y., Kim H., Shah J.B., Peake J., Ferman B., Medvedev S., Murtha T., Barger C.J. CCNE1 copy-number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Rep. Med. 2021;2:100394-1–100394-17. - PMC - PubMed
    1. Cramer D.W. The epidemiology of endometrial and ovarian cancer. Hematol. Oncol. Clin. North Am. 2012;26:1–12. - PMC - PubMed
    1. Kok Y.P., Guerrero Llobet S., Schoonen P.M., Everts M., Bhattacharya A., Fehrmann R.S.N., van den Tempel N., van Vugt M.A.T.M. Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors. Oncogenesis. 2020;9:88. - PMC - PubMed
    1. Guerrero Llobet S., van der Vegt B., Jongeneel E., Bense R.D., Zwager M.C., Schröder C.P., Everts M., Fehrmann R.S.N., de Bock G.H., van Vugt M.A.T.M. Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer. NPJ Breast Cancer. 2020;6:40. - PMC - PubMed
    1. Gorecki L., Andrs M., Korabecny J. Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. Cancers (Basel) 2021;13:795. - PMC - PubMed

Publication types